(SS) is a medicinal herb commonly used in Asia to treat anemia, menoxenia and rheumatism. However, its effect of diabetes-induced renal damage and mechanisms of action against advanced glycation end-products (AGEs) are unclear. In this study, we evaluated the effects of SS on diabetes-induced renal damage and explored the possible underlying mechanisms using db/db type 2 diabetes mice. db/db mice were administered SS extract (50 mg/kg) orally for 6 weeks. SS-treated group did not change body weight, blood glucose and glycated hemoglobin (HbA1c) levels. However, SS treatment reversed diabetes-induced dyslipidemia and urinary albumin/creatinine ratio in db/db mice. Moreover, SS administration showed significantly increased protein expression of nuclear factor erythroid 2-related factor 2 (Nrf2), which is a transcription factor for antioxidant enzyme. SS significantly upregulated glyoxalase 1 (Glo1) and NADPH quinine oxidoreductase 1 (NQO1) expression but reduced CML accumulation and downregulated receptor for AGEs (RAGE). Furthermore, SS showed significant decrease of periodic acid⁻Schiff (PAS)-positive staining and AGEs accumulation in histological and immunohistochemical analyses of kidney tissues. Taken together, we concluded that SS ameliorated the renal damage by inhibiting diabetes-induced glucotoxicity, dyslipidemia and oxidative stress, through the Nrf2/antioxidant responsive element (ARE) stress-response system.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163801 | PMC |
http://dx.doi.org/10.3390/ijms19092774 | DOI Listing |
Cytotechnology
April 2025
Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Because acute kidney injuries (AKI) are one of the critical health problems worldwide, studies on the risk factors, mechanisms, and treatment strategies seem necessary. Glycerol (GLY), known to induce cell necrosis via myoglobin accumulation in renal tubules, is widely used as an AKI model. This study aimed to evaluate the protective effects of gallic acid (GA) against GLY-induced AKI.
View Article and Find Full Text PDFPak J Med Sci
January 2025
Rong Zou Department of Nephrology, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan Province 421002, P.R. China.
Objective: To explore the effects of hybrid blood purification on nutritional status and cardiovascular events in patients with end-stage renal disease (ESRD).
Methods: A total of 135 patients with ESRD who received treatment in The Affiliated Nanhua Hospital of Hengyang Medical School from March 2021 to June 2023 were included in this retrospective study. Of them, 66 patients were treated with hemodialysis purification (hemodialysis group), and 69 patients underwent hybrid blood purification (hybrid group).
Rev Cardiovasc Med
January 2025
Department of Cardiology, Gazi University Faculty of Medicine, 06560 Ankara, Turkey.
Background: Hypertension-mediated organ damage (HMOD) is a critical complication of hypertension that can present with cardiac, retinal, and renal manifestations and affect patient outcomes. Serum signal peptide, CUB (complement C1r/C1s, Uegf, and Bmp1) domain, and epidermal growth factor-like domain-containing protein 1 (SCUBE-1), a novel biomarker implicated in vascular pathology, shows promise for detecting HMOD. This study aims to explore the relation between SCUBE-1 levels and HMOD in hypertensive patients.
View Article and Find Full Text PDFA previously healthy 30-year-old woman experienced worsening back pain, fatigue, weakness, loss of appetite, and facial puffiness. After 18 months of these symptoms, she was diagnosed with multiple myeloma, which was also damaging her kidneys. The treatment involved a combination of medications and blood transfusions, leading to improved kidney function.
View Article and Find Full Text PDFJ Clin Med Res
January 2025
Internal Medicine Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Background: Systemic lupus erythematosus (SLE) can affect a plethora of organ systems and cause organ damage due to the disease process and medication toxicity, notably corticosteroids. Patients with SLE often suffer irreversible organ damage. Older age, glucocorticoid use, longer disease duration, and disease activity all represent risk factors for organ damage.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!